Do not recommend - Avis employé Quality Analyst Merck

1,0
31 juil. 2025
Recommande
Approbation du PDG
Perspective commerciale

Avantages

While there is a lot of variety in the work, and opportunities to learn new skills

Inconvénients

The work environment is extremely toxic, with a culture that unfortunately encourages bullying rather than fostering a collaborative or supportive atmosphere. There is no support from senior management, leaving employees to feel isolated and unsupported in the workplace. The team dynamic is largely based on finger-pointing and blaming, rather than constructive feedback or training. This creates a high-pressure, stressful environment where learning and personal development are not prioritized. On top of this, the physical environment is far from ideal. There is no on-site canteen, and a break room which is too small for the number of employees making it difficult to relax during breaks which can lead to feelings of exhaustion and burnout. Overall, the combination of a toxic culture, lack of support, and constant stress makes it difficult to recommend this job to anyone looking for a positive and healthy workplace.

Découvrez plus d’avis sur Merck

5,0
29 juin 2026
Recommande
Approbation du PDG
Perspective commerciale

Avantages

Benefits and pay are great

Inconvénients

Depends on manager and organization is how your experience and work life balance will be

4,0
30 juin 2026
Recommande
Approbation du PDG
Perspective commerciale

Avantages

Great benefits like medical/dentist/vision, pension, stock option, 401k match. Co workers are excellent, pretty good on site symposiums, lot of diversity clubs/activities. Innovation is extremely welcomed. Diversity in research portfolio. AI/ML is heavily invested to make databases more efficient.

Inconvénients

Micro managing, especially within the biologics department, potentially others. Promotions are limited, and pay bump is poor. Company invests too much in buying companies rather than keeping talent - lay offs let go of great talented people. Merck is afraid of investing into exploratory biology and doesn’t take risk - they even admit they would rather see other companies clinical data or R&D data rather than taking a risk. Although it’s slow going in building new software, current databases are slow and needs much improvement. Extremely poor work/life balance.

Voir les avis par: Utile|Évaluation|Date|Tout